Deferoxamine
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Anemia Medications | Deferoxamine | 5mg/kg IV weekly | Administer Post-HD or During Last Hour of HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 561 | 30-35 | 6 | N/A | <10 | 2-2.5 | N/A | 13-27 (N/A) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00746
- Deferoxamine. In AHFS: Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2012.